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A G protein-coupled receptor agonist, angiotensin II
(AngII), induces epidermal growth factor (EGF) receptor
(EGFR) transactivation possibly through metallopro-
tease-dependent, heparin-binding EGF (HB-EGF) shed-
ding. Here, we have investigated signal transduction of
this process by using COS7 cells expressing an AngII re-
ceptor, AT1. In these cells AngII-induced EGFR transacti-
vation was completely inhibited by pretreatment with a
selective HB-EGF inhibitor, or with a metalloprotease in-
hibitor. We also developed a COS7 cell line permanently
expressing a HB-EGF construct tagged with alkaline
phosphatase, which enabled us to measure HB-EGF shed-
ding quantitatively. In the COS7 cell line AngII stimu-
lated release of HB-EGF. This effect was mimicked by
treatment either with a phospholipase C activator, a Ca2
ionophore, a metalloprotease activator, or H2O2. Con-
versely, pretreatment with an intracellular Ca2 antago-
nist or an antioxidant blocked AngII-induced HB-EGF
shedding. Moreover, infection of an adenovirus encoding
an inhibitor of Gq markedly reduced EGFR transactiva-
tion and HB-EGF shedding through AT1. In this regard,
AngII-stimulated HB-EGF shedding was abolished in an
AT1 mutant that lacks Gq protein coupling. However, in
cells expressing AT1 mutants that retain Gq protein cou-
pling, AngII is still able to induce HB-EGF shedding. Fi-
nally, the AngII-induced EGFR transactivationwas atten-
uated in COS7 cells overexpressing a catalytically
inactivemutant of ADAM17. From these datawe conclude
that AngII stimulates ametalloprotease ADAM17-depend-
ent HB-EGF shedding through AT1/Gq/phospholipase
C-mediated elevation of intracellular Ca2 and reac-
tive oxygen species production, representing a key
mechanism indispensable for EGFR transactivation.
Angiotensin II (AngII)1 and its G protein-coupled receptor
(GPCR), the AngII type-1 receptor (AT1), play critical roles in
mediating cardiovascular diseases such as hypertension, ath-
erosclerosis, and restenosis after vascular injury (1, 2). It is
widely believed that AngII promotes these diseases by inducing
vascular remodeling that involves hypertrophy, hyperplasia,
and migration of vascular smooth muscle cells (VSMCs) (3, 4).
We and others have shown that AngII promotes these cellular
effects by “trans”-activation of the epidermal growth factor
receptor (EGFR) through the AT1 receptor (5, 6). Similar to
EGF stimulation, AngII transactivates EGFR, which recruits
the adaptor proteins Shc and Grb2, leading to the activation of
the extracellular signal-regulated kinase (ERK) cascade (7).
Moreover, EGFR transactivation by AngII also leads to critical
signaling responses such as activation of Akt/protein kinase B,
p70 S6 kinase, and p38 mitogen-activated protein kinase
(MAPK) in VSMCs (5, 8, 9). These data suggest that EGFR
transactivation is one of the main points of convergence by
which AngII induces several pathophysiological functions in its
target organs (10).
Recently, several interesting observations have been made
regarding the possible components involved in EGFR transac-
tivation by GPCRs. First, EGFR transactivation by GPCRs
appears to require a second messenger directly and/or signal
transduction pathways operated by second messengers, such as
elevation of intracellular Ca2 (11), activation of protein kinase
C (12), and generation of reactive oxygen species (ROS) (13). In
this regard, the EGFR transactivation by AngII seems to in-
volve elevation of intracellular Ca2 concentration and produc-
tion of ROS in VSMCs (7, 14–16). Second, a cytosolic non-
receptor tyrosine kinase such as Src or PYK2 may be involved
in the EGFR transactivation (17, 18). Both kinases have been
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shown to be activated by AngII in VSMCs (19–21). Third, an
attractive mechanism for the EGFR transactivation by a GPCR
was proposed recently that involves metalloprotease-depend-
ent EGFR ligand production from its membrane-bound precur-
sor (9, 22).
The EGF ligand family consists of EGF, heparin binding-
EGF like growth factor (HB-EGF), transforming growth fac-
tor-, epiregulin, amphiregulin, epigen, neuregulins, and beta-
cellulin (23). Among these, HB-EGF has been most implicated
in vascular remodeling because it is a potent mitogen and
chemotactic factor for VSMCs and its expression is enhanced in
vascular lesions such as atherosclerosis and restenosis follow-
ing angioplasty (24, 25). Like other members of the EGF ligand
family, HB-EGF is synthesized as a transmembrane precursor
“pro-HB-EGF” that is proteolytically cleaved (“shedding”) to
release a biologically active soluble growth factor (26). Re-
cently, many GPCR agonists appear to mediate EGFR trans-
activation through this metalloprotease-dependent HB-EGF
shedding (27). We and others also showed the requirement of
HB-EGF for EGFR transactivation through the AT1 receptor
(9, 28, 29). However, the identity of the metalloprotease as well
as the detailed signaling mechanisms of HB-EGF shedding by
AngII in relation to G protein coupling, second messengers, and
upstream kinases are largely unknown.
In this study we established a COS7 cell line expressing
alkaline phosphatase (AP)-conjugated HB-EGF that enabled
us to measure the HB-EGF shedding activity quantitatively.
By using this system together with molecular and pharmaco-
logical tools including several AT1 receptor mutants, we have
elucidated the involvement of heterotrimetric G protein cou-
pling and second messengers (Ca2 and ROS) in a critical step
of a metalloprotease-dependent HB-EGF production. The find-
ings presented here will provide a novel molecular insight by
which AngII contributes to cardiovascular diseases.
EXPERIMENTAL PROCEDURES
Materials—Phospho-specific antibodies for Tyr1068-phosphorylated
EGFR and for Tyr1007-Tyr1008-phosphorylated JAK2 were purchased
from BIOSOURCE. Antibody against EGFR was purchased from Santa
Cruz Biotechnology. Antibody against hemagglutinin was purchased
from Zymed Laboratories Inc.. YM-254890 was a gift from Yamanouchi
Pharmaceutical Co. AngII, N-acetylcysteine (NAC), and H2O2 were
purchased from Sigma. A23187, 1,2-bis(2-aminophenoxy)ethane-
N,N,N,N-tetraacetic acid tetra(acetoxymethyl)ester, GF109203X,
TMB-8, phorbol 12-myristate 13-acetate, CRM197, m-3M3FBS,
p-aminophenylmercuric acetate (APMA), and 2R-[(4-biphenylsulfo-
nyl)amino]-N-hydroxy-3-phenylpropionamide (BiPS) were purchased
from Calbiochem. BiPS was originally described as a matrix metallo-
protease-2 and matrix metalloprotease-9 inhibitor (30). However, our
subsequent findings demonstrated the ability of BiPS to inhibit EGFR
transactivation by AngII that was not mediated by matrix metallopro-
teases (31). BiPS shares its structure with CGS27023, which can also
inhibit EGFR transactivation by AngII (31). CGS27023 was demon-
strated to block the catalytic activity of ADAM9 and ADAM17 (32),
suggesting that BiPS could act as an ADAM inhibitor as well.
Cell Lines—COS7 cells were obtained from the American Type Cul-
ture Collection and subcultured as described previously (33). COS7 cells
permanently expressing HB-EGF were established by antibiotic selec-
tion after transfection with the AP-tagged HB-EGF (HBEGF-AP) plas-
mid (34) as described previously (33). A Chinese hamster ovary cell line
stably expressing wild type rat AT1 (AT1WT) and its deletion mutants,
AT1-(1–309) and AT1-(1–317), were established as described previously
(35). The AT1 receptors expressed in these cells have a comparable Kd
and Bmax (35).
Adenoviral Infection—Adenovirus constructs encoding wild type rat
AT1 receptor and a carboxyl-terminal mutant, AT1Y319F, in which
carboxyl-terminal Tyr319 was replaced with Phe319 were generated as
described previously (29, 36, 37). The adenoviral vector containing the
inhibitor of Gq signaling (GqI), comprised of the amino acids 305–359 of
murine Gq, was constructed as described previously (38). Each adeno-
virus titer (m.o.i.) was determined by Adeno-XTM rapid titer kit (BD
Biosciences). Confluent COS7 cells were infected with adenovirus at
50–100 m.o.i. for 2 days as described previously (33). Transfection
efficiency was estimated to be 95% as defined by infection with ade-
novirus (50 m.o.i.) encoding green fluorescent protein.
Retroviral Infection—C-terminal hemagglutinin-tagged catalytically
inactive/dominant negative ADAM17 (dnADAM17), in which Glu406
was replaced with Ala (39), was cloned into the pBM-IRES-PURO
retroviral vector (40). For retroviral infection, 4  105 cells were seeded
into 25-cm2 tissue culture flasks and cultured for 24 h prior to infection.
Cells were incubated with 5 ml of virus stock for 12 h in the presence of
4 g/ml Polybrene and then replenished with fresh media. Cells were
then grown for 48 h prior to passaging into media containing 6 g/ml
puromycin. Resistant cells were used in subsequent experiments (40).
Plasmid Transfection—Plasmids encoding rat AT1WT and
AT1Y319F were generated as described previously (35, 41). COS7 cells
were transiently transfected with the plasmids by using FuGENE6
(Roche Applied Science) for 24 h with 10% serum, and then the cells
were serum-starved for 24 h before stimulation.
FIG. 1. Involvement of metalloprotease-dependent HB-EGF
shedding in AngII-induced EGFR transactivation in COS7 cells
expressing the AT1 receptor. A, COS7 cells infected with an adeno-
virus (100 m.o.i.) encoding the AT1 receptor or control LacZ were stim-
ulated by AngII (100 nM) for the indicated time periods. Cell lysates
were immunoblotted (IB) with antibodies against Tyr1068-phosphoryl-
ated EGFR (EGFR-p) and total EGFR as indicated. B, COS7 cells
infected with adenovirus encoding AT1 receptor (100 m.o.i.) were pre-
treated with a selective inhibitor of HB-EGF, CRM197 (10 g/ml), or a
metalloprotease inhibitor, BiPS (10 M), for 30 min and stimulated with
AngII (100 nM) for 5 min. Cell lysates were immunoblotted (IB) with
antibodies against Tyr1068-phosphorylated EGFR (EGFR-p), total
EGFR, and Tyr1007-Tyr1008-phosphorylated JAK2 (JAK2-p) as indi-
cated. C, COS7 cells permanently expressing HBEGF-AP construct
were infected with AT1 receptor adenovirus (100 m.o.i.), and stimulated
with or without AngII (100 nM) for the indicated time period. AP activity
in the medium was determined. Results are the means  S.E. (n  3).
*, p  0.05 as compared with non-stimulated control at each time point.
basal, control sample.
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HB-EGF Shedding Assay—48 h after AT1 receptor transfection,
COS7-HBEGF-AP cells were pre-incubated in fresh phenol red-free
Dulbecco’s modified Eagle’s medium for 30 min in the presence or
absence of inhibitors and then stimulated by agonists up to 60 min. The
HB-EGF-AP secreted into the medium was assessed by measuring
alkaline phosphatase activity as described previously (33).
Western Blotting—Cell lysates were subjected to sodium dodecyl
sulfate polyacrylamide gel electrophoresis and electrophoretically
transferred to a nitrocellulose membrane as described previously (42).
The membranes were then exposed to primary antibodies overnight at
4 °C. After incubation with the peroxidase-linked secondary antibody
for 1 h at room temperature, the immunoreactive proteins were visu-
alized by a chemiluminescence reaction kit (Chemicon).
Intracellular Ca2 ([Ca2]i) Measurements—[Ca
2]i was measured
as described previously (43). VSMCs subcultured on coverslips were
loaded in Hanks’ balanced salt solution with 3 M fura 2/AM at room
temperature for 45 min in the dark and then washed three times with
fura 2-free Hanks’ balanced salt solution to allow for complete de-
esterification of the dye for 15–60 min. Under these conditions, com-
partmentalization of the dye was minimal. The coverslips were
mounted in a custom-designed bath in the stage of a S300 Axiovert
Nikon inverted microscope equipped with a C & L Instruments fluo-
rometer system. The fura 2 fluorescence was acquired at a frequency of
1 Hz, and [Ca2]I values were then obtained as described (43).
Statistic—Data were analyzed by using the Student’s t test. The
mean  S.E. was determined with a significance level of p  0.05.
Results are representative of at least three separate experiments.
RESULTS
Metalloprotease and HB-EGF-dependent EGFR Transactiva-
tion by AngII in COS7 Cells—Using COS7 cells, we have es-
tablished a system to examine the mechanism of EGFR trans-
activation through a GPCR, AT1. For this purpose, COS7 cells
were infected with an adenovirus encoding AT1. Compared
with the COS7 cells infected with the control adenovirus en-
coding LacZ, AngII stimulation resulted in marked phospho-
rylation of the EGFR at Tyr1068, a Grb2-binding site, in COS7
cells expressing AT1 in a time-dependent manner (Fig. 1A). To
determine the involvement of metalloprotease activation in
AngII-induced EGFR transactivation in COS7 cells, the effect
of a metalloprotease inhibitor, BiPS, on EGFR phosphorylation
at Tyr1068 was examined. As we observed previously in VSMCs
(31), BiPS completely inhibited AngII-induced EGFR transac-
tivation in COS7 cells (Fig. 1B). To demonstrate the critical
involvement of HB-EGF in AngII-induced EGFR transactiva-
tion, the effect of a diphtheria toxin analogue, CRM197, which
acts as a specific inhibitor against primate HB-EGF was exam-
ined in regard to EGFR phosphorylation. Pretreatment of
CRM197 markedly inhibited AngII-induced EGFR transactiva-
tion in COS7 cells expressing AT1 (Fig. 1B). In contrast, both
BiPS and CRM197 did not affect JAK2 phosphorylation at
Tyr1007-Tyr1008 stimulated by AngII. These results clearly
demonstrated that COS7 cells expressing AT1 provide an in-
teresting model for studying the mechanism of AngII-induced
EGFR transactivation involving metalloprotease-dependent
HB-EGF production.
To examine the detailed mechanism of metalloprotease-de-
pendent HB-EGF shedding, we took advantage of a reporter
assay system using transfection of the HB-EGF-AP plasmid, an
established assay for HB-EGF shedding (34). In COS7 cells
permanently expressing this plasmid, we evaluated the shed-
ding activity of HB-EGF by measuring AP activity secreted into
the medium. In these cells, there is a gradual but statistically
significant accumulation of AP activity in a non-stimulated
condition during pre-incubation, suggesting a presence of basal
shedding activity of HB-EGF. However, basal shedding was not
further enhanced up to 60 min, suggesting a saturated nature
FIG. 2. Involvement of second mes-
sengers in AT1 receptor-mediated
HB-EGF shedding. A and B, COS7-
HBEGF-AP cells were infected with AT1
receptor adenovirus (100 m.o.i.). After
pretreatment with an intracellular Ca2
antagonist, TMB-8 (100 nM), or an antiox-
idant, NAC (20 mM), for 30 min (A) or
with a protein kinase C inhibitor,
GF109203X (2 M) (B), cells were stimu-
lated with AngII (100 nM) for 60 min, and
AP activity in the medium was deter-
mined. C, after pretreatment with BiPS
(10 M) or its vehicle, Me2SO (DMSO;
0.1%), for 30 min, COS7-HBEGF-AP cells
were stimulated with a metalloprotease
activator, APMA (30 M), a Ca2 iono-
phore, A23187 (10 M), or H2O2 (1 mM) for
60 min, and AP activity in the medium
was determined. D, COS7-HBEGF-AP
cells were pretreated with or without
NAC (20 mM) for 30 min, cells were stim-
ulated with A23187 (10 M) for 60 min,
and AP activity in the medium was deter-
mined. Results are the means  S.E. (n 
3). *, p  0.05 as compared with the basal
control; †, p  0.05 as compared with the
stimulated control.
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of the basal shedding activity. In contrast, a marked and time-
dependent enhancement of AP activity was observed when cells
were treated with AngII, thus demonstrating the ability of
AngII to stimulate HB-EGF shedding. In addition, AngII-in-
duced HB-EGF shedding was completely inhibited by BiPS
(data not shown). These findings further indicated that the
HB-EGF-AP assay system in a cell line expressing AT1 would
be an ideal tool to study the signal transduction mechanism of
metalloprotease-dependent HB-EGF shedding and subsequent
EGFR transactivation by AngII.
AngII Stimulates HB-EGF Shedding through Intracellular
Ca2 Elevation and ROS Production—Previous studies have
shown the involvement of Ca2 and ROS as critical signal
intermediates in EGFR transactivation through AT1 in VSMCs
(7, 14, 15). Also, protein kinase C may exist upstream of the
ROS production (16). In COS7 cells, AngII-induced HB-EGF
shedding was completely blocked by pretreatment with TMB-8,
an intracellular Ca2 antagonist, as well as by NAC, a potent
antioxidant (Fig. 2A). In contrast, a protein kinase C inhibitor,
GF109203X, had no significant effect on AngII-induced HB-
EGF shedding (Fig. 2B), whereas it markedly inhibited 100 nM
phorbol 12-myristate 13-acetate-induced HB-EGF shedding in
the COS7 cells (data not shown). Stimulation with a metallo-
protease activator, APMA, a Ca2 ionophore, A23187, and
H2O2 resulted in enhanced HB-EGF shedding that was inhib-
ited by pretreatment with BiPS. The basal shedding activity
was also partially inhibited by BiPS (Fig. 2C). In addition, we
confirmed that APMA and A23187 as well as H2O2 induced
EGFR transactivation in COS7 cells (data not shown). More-
over, HB-EGF shedding stimulated by A23187 was completely
blocked by NAC (Fig. 2D), whereas H2O2-induced HB-EGF
shedding was minimally affected by TMB-8 (data not shown).
FIG. 3. Requirement of Gq activation for HB-EGF shedding and EGFR transactivation by AngII. A, COS7 cells were infected with
adenovirus encoding AT1 receptor (100 m.o.i.) together with GqI (50 m.o.i.) or control vector (50 m.o.i.). Cells were stimulated with 100 nM AngII,
and peak stimulation of intracellular Ca2 concentration was determined. B, COS7-HBEGF-AP cells were infected with adenovirus encoding AT1
receptor (100 m.o.i.) together with GqI (50 m.o.i.) or control vector (50 m.o.i.). The cells were stimulated with AngII (100 nM) for 60 min, and AP
activity in the medium was determined. C, COS7 cells with the infection described above were stimulated with 100 nM AngII for 5 min. Cell lysates
were immunoblotted (IB) with antibodies against Tyr1068-phosphorylated EGFR (EGFR-p) and total EGFR as indicated. D, COS7-HBEGF-AP cells
were infected with AT1 receptor adenovirus (100 m.o.i.). After pretreatment with a selective Gq inhibitor, YM-254890 (YM; 10 M), or its vehicle,
Me2SO (DMSO; 0.1%), for 10 min, cells were stimulated with AngII (100 nM) for 60 min, and AP activity in the medium was determined. Results
are the means  S.E. (n  3). *, p  0.05 as compared with the basal control; †, p  0.05 as compared with the stimulated control.
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These results suggest that, in COS7 cells, intracellular Ca2
elevation and subsequent ROS production are required for a
metalloprotease activation that is responsible for EGFR trans-
activation through AT1.
Requirement of Gq Coupling for HB-EGF Shedding through
AT1—In addition to Gq, AT1 has been shown to couple Gi, G12,
and/or G13, depending on cell type (44, 45). Although intra-
cellular Ca2 elevation through AT1 is primarily believed to
require Gq/PLC-, additional mechanisms involving G12/
13, G, PLC-, and/or L-type Ca2 channel have been pro-
posed (44). Activation of Gq has been proposed to participate
in a GPCR-induced EGFR transactivation (46), whereas pos-
sible participation of the G subunit was reported in a
metalloprotease/EGFR-dependent ERK activation by 2A-ad-
renergic receptor in human embryonic kidney cells (47).
Therefore, we examined the contribution of Gq signaling in
HB-EGF shedding induced by AngII by using an adenovirus
encoding the C-terminal fragment of Gq termed GqI, a se-
lective Gq inhibitor (48), as well as a novel Gq selective
pharmacological inhibitor, YM-254890 (49). GqI markedly
inhibited intracellular Ca2 elevation (Fig. 3A), HB-EGF
shedding (Fig. 3B), and EGFR transactivation (Fig. 3C) in-
duced by AngII through AT1. YM-254890 also inhibited HB-
EGF shedding induced by AngII but not by A23187 (Fig. 3D).
In addition, a selective PLC activator, m-3M3FBS (50), stim-
ulated HB-EGF shedding (Fig. 4A) as well as EGFR transac-
tivation (Fig. 4B) in COS7 cells. These data suggest the
requirement of Gq-dependent PLC- activation for the met-
alloprotease activation involved in EGFR transactivation op-
erated through AT1.
Effect of AT1 Mutants on HB-EGF Shedding—Analysis of
AT1 mutation has been proven to be a useful tool for studying the
mechanistic insights not only of ligand or G protein interaction
but also of receptor internalization/desensitization as well as
downstream signal transduction (10, 51). By using several AT1
receptor truncationmutants, a previous study demonstrated that
a particular cytosolic carboxyl-terminal region (310–317) of the
AT1 receptor is essential for G protein coupling and activation of
Gq (35). We found that AngII-induced HB-EGF shedding re-
mained intact in cells stably expressing a truncated mutant that
still contains G protein coupling, AT1-(1–317), but was abolished
in cells stably expressing AT1-(1–309), which lacks G protein
coupling (Fig. 5A). The AT1 receptors expressed in these cells
have a comparable Kd and Bmax (35). We also confirmed that
AngII-induced EGFR transactivation remained intact in COS7
cells expressing AT1-(1–317) (data not shown). However, recent
studies using distinct mutants of AT1 demonstrated G protein-
independent activation of tyrosine kinases (36, 37, 52). In partic-
ular, it has been reported that in a mutant of a conserved YIPP
motif in the C terminus of AT1, AT1Y319F, EGFR transactivation
was attenuated, whereas Gq coupling remained intact (37). By
contrast, we observed comparable HB-EGF shedding by
AT1Y319F in COS7 cells (Fig. 5B). We also confirmed that
AT1Y319F was able to stimulate EGFR transactivation (Fig. 5C)
and intracellular Ca2 elevation (Fig. 5D). Thus, these results
support our notion that a metalloprotease responsible for HB-
EGF shedding and subsequent EGFR transactivation by AT1 is
triggered through the interaction between Gq and AT1 upon
AngII binding.
Involvement of ADAM17 in EGFR Transactivation through
AT1—Several ADAM family metalloproteases have been impli-
cated in the HB-EGF shedding required for EGFR transacti-
vation by distinct GPCR agonists (53–56). Because ADAM17
has been critically implicated in HB-EGF shedding (57, 58), we
have examined the involvement of this metalloprotease in
EGFR transactivation induced by AngII. As shown in Fig. 6A,
transfection of dnADAM17 but not control vector by retrovirus
significantly inhibited EGFR transactivation induced by AngII
through AT1. Also, EGFR transactivation induced by A23187
and H2O2 but not stimulation by EGF was blocked by dn-
ADAM17 (Fig. 6B). Taken together, ADAM17 represents a
metalloprotease sensitive to AT1/Gq-operated second messen-
ger signals, leading to the EGFR transactivation.
DISCUSSION
In the present study we have established a cell system that
enabled us to elucidate a signal transduction mechanism of
metalloprotease-dependent HB-EGF shedding by AngII, an in-
dispensable step for EGFR transactivation via the AT1 recep-
tor. Although there are several reports thus far describing the
role of metalloproteases in mediating EGFR transactivation
and subsequent functions induced by many GPCRs (53–56),
very few of them have focused on the immediate signal trans-
ductions (G protein-coupling and second messengers) required
for the metalloprotease activation by a GPCR agonist. We
found that Gq-mediated intracellular Ca
2 mobilization and
ROS production are essential for metalloprotease-dependent
HB-EGF production by a GPCR, AT1.
In the EGF ligand family, HB-EGF has been intensively
reported to be a critical EGFR ligand for EGFR transactivation
(22, 26, 27). However, there is the possibility for the participa-
tion of other EGF ligands such as betacellulin, which promotes
VSMC proliferation (59, 60) and migration (61) and is ex-
pressed in VSMCs (61) and atherosclerotic lesions (60, 62).
However, in our system EGFR transactivation by AngII was
completely inhibited by pretreatment with CRM197. These
results suggest that HB-EGF production may largely partici-
pate in EGFR transactivation within COS7 cells stimulated
through the AT1 receptor. This notion is in good agreement
with similar findings in cultured VSMCs (7), neonatal myo-
cytes (29, 53), and endothelial cells (28), where AngII physio-
logically transactivates EGFR. Thus, our system in COS7 cells
could represent a useful model to study the molecular mecha-
nism of the EGFR transactivation.
Because previous studies suggested the involvement of sec-
ond messengers in AngII-induced EGFR transactivation in
VSMCs (5, 16, 63), we have further investigated their relation
toward the metalloprotease activation. Our results presented
here suggest that Gq/PLC-mediated intracellular Ca
2 eleva-
tion and ROS production but not protein kinase C activation
are required for HB-EGF shedding mediated through AT1.
However, taken together with the previous finding that HB-
FIG. 4. A selective PLC agonist stimulates HB-EGF shedding
and EGFR transactivation. A, COS7-HBEGF-AP cells were stimu-
lated with a selective PLC agonist, m-3M3FBS (m3M; 50 M), for 60
min, and AP activity in the medium was determined. B, COS7 cells
were stimulated with m-3M3FBS (m3M; 50 M) for 10 min. Cell lysates
were immunoblotted with antibodies against Tyr1068-phosphorylated
EGFR (EGFR-p) and total EGFR as indicated. Results are the means 
S.E. (n  3). *, p  0.05 as compared with the basal control.
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EGF shedding can be induced by activation of protein kinase C
(24), elevation of intracellular Ca2 (64), or ROS generation
(33, 65) in distinct cell systems, it is likely that one or more
metalloprotease(s) might be responsible for EGFR transactiva-
tion by extracellular stimuli depending on the type of cells or
tissues utilized.
By using deletion mutants of the AT1 receptor, we have
demonstrated the requirement of a C-tail structure between
residues 310–317 for HB-EGF shedding by AngII, whereas
additional C-tail sequences are dispensable. Previous studies
with AT1 receptor mutants showed that these C-tail lesions
close to the seventh transmembrane region is essential for Gq
coupling (35), thus confirming the important role of Gq-medi-
ated second messengers for AT1-operated HB-EGF shedding.
The HB-EGF shedding was further blocked by selective Gq
inhibitors in the present study. In conflict with our findings,
several recent reports have argued against the requirement of
G protein-derived second messengers for tyrosine kinase acti-
vation thorough the AT1 receptor (36, 37, 52). Seta and
Sadoshima showed that phosphorylation of the AT1 receptor at
Tyr319 is a prerequisite for EGFR transactivation because it
can provide a docking site for protein-protein interaction, a
proposed mechanism for the transactivation (37). However,
this mutant is able to stimulate HB-EGF shedding and EGFR
transactivation in our study. The mutant also stimulated ERK
in COS7 cells that was blocked by an EGFR kinase inhibitor or
a metalloprotease inhibitor (66). The discrepancy may be due to
the different nature of the cells utilized together with distinct
experimental strategies (Seta and Sadoshima used cells ex-
pressing an exogenous EGFR gene) (37).
Several ADAM family metalloproteases have been identified
as mediating EGFR ligand shedding and/or EGFR transactiva-
tion in response to distinct GPCR agonists (53–56). Our data
using a dnADAM17 mutant suggest that ADAM17, at least in
part, mediates AngII-induced HB-EGF shedding and subse-
quent EGFR transactivation in COS7 cells. However, Yan et al.
havereportedthataGPCRagonist,bombesin, inducesADAM10-
dependent HB-EGF shedding and EGFR transactivation in
COS7 cells (67). Although bombesin receptors expressed in
mammalian cells mainly coupled to Gq (68), no information was
provided regarding the upstream signal transduction pathway
leading to ADAM10 activation by bombesin except for an in-
ducible association event between CD9, ADAM10, and HB-
EGF in response to bombesin (67). Thus far, only one paper has
reported the identity of ADAM responsible for HB-EGF shed-
ding and EGFR transactivation induced by AngII, and it ap-
pears to be ADAM17 but not ADAM10 in a kidney carcinoma
cell line, ACHN (69). However, this study also lacks any infor-
mation regarding the upstream events of the ADAM17 activa-
tion. Recent reports also suggest ADAM17 as the major shed-
dase of HB-EGF, whereas ADAM10 is suggested to be the
major sheddase of EGF and betacellulin (40, 70, 71), thus
FIG. 5. Effect of AT1 receptor muta-
tion on AngII-induced HB-EGF shed-
ding and EGFR transactivation. A,
Chinese hamster ovary cells stably ex-
pressing AT1WT, AT1-(1–309), or AT1-(1–
317) were transiently transfected with
the HBEGF-AP cDNA construct for 48 h
and stimulated with AngII (100 nM) for 60
min. AP activity in the medium was de-
termined. B, COS7-HBEGF-AP cells were
transfected with AT1WT or AT1Y319F
and stimulated with AngII (100 nM) for 60
min. AP activity in the medium was de-
termined. C, COS7 cells infected with ad-
enovirus encoding AT1WT (100 m.o.i.) or
AT1Y319F (100 m.o.i.) were stimulated
with AngII (100 nM) for 5 min. Cell lysates
were immunoblotted (IB) with antibodies
against Tyr1068-phosphorylated EGFR
(EGFR-p) and total EGFR as indicated.
D, COS7 cells infected with above adeno-
virus were stimulated with AngII (100
nM), and peak stimulation of intracellular
Ca2 concentration was determined. Re-
sults are the means  S.E. (n  3). *, p 
0.05 as compared with the basal control;
†, p  0.05 as compared with the stimu-
lated control.
HB-EGF Shedding by Angiotensin II 26597
 at UQ Library on September 5, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
supporting the role of ADAM17 in mediating AngII-induced
EGFR transactivation.
How does the upstream signal transduction pathway(s) ac-
tivate ADAM17 in response to AngII? We have proposed the
role of ROS production as a critical step of the HB-EGF shed-
ding and EGFR transactivation in COS7 cells as well as in
VSMCs (5, 63). Our data presented here further suggest that
ROS production by AngII could lead to ADAM17 activation.
ADAM could be activated by phosphorylation and/or associa-
tion with Src homology 3 domain-containing adaptors (26, 72).
Therefore, AngII-produced ROS may activate ROS-sensitive
protein kinases to phosphorylate an intracellular region of
ADAM17- and/or ADAM-associated adaptor proteins that trig-
ger the catalytic activation of ADAM17. To support this theory,
Fisher et al. recently demonstrated that H2O2-induced EGFR
transactivation was blocked by a p38 MAPK inhibitor (65).
However, the requirement of p38 MAPK for AngII-induced
activation of ADAM17 is unlikely, because we have shown that
p38 MAPK exists downstream of the metalloprotease-depend-
ent EGFR transactivation induced by AngII (9). In fact, we
could not block HB-EGF shedding induced by AngII in COS7
cells by using a p38 MAPK inhibitor,2 suggesting the presence
of other ROS-sensitive kinase(s) required for ADAM17 activa-
tion. This discrepancy may be due to the difference between the
extracellular addition of ROS and intracellular production of
ROS by AngII under the experimental conditions. In this re-
gard, Fisher et al. showed that not only ADAM17 but also
ADAM10 is involved in H2O2-induced EGFR transactivation
(65). The other candidate kinase could be a Src family kinase.
c-Src was implicated in a metalloprotease/EGFR-dependent
ERK activation by 2A-adrenergic receptor (47). Alternatively,
ROS could directly activate ADAM17 by oxidizing electrophilic
thiol groups critical for ADAM17 activity, such as through
regulation of the chaperone or inhibitory functions of the
prodomain (73–75).
In summary, we have demonstrated that AT1-mediated Gq
activation and resultant intracellular Ca2 elevation and ROS
generation are essential for AngII-induced HB-EGF shedding.
Because HB-EGF-dependent EGFR transactivation partici-
pates in cardiovascular remodeling, our data presented here
will provide novel therapeutic targets, such as second messen-
ger-sensitive ADAM17, for treatment and/or prevention of
cardiovascular diseases.
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